Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

Georgia Life Sciences Partners with U.S. Chamber Foundation to Bring Real-World Innovation to Georgia Classrooms

60 + high school students tackle real industry challenges through national EPIC program


July 7, 2025

ATLANTA – Georgia Life Sciences (GLS) has successfully completed its first collaboration with the U.S. Chamber of Commerce Foundation’s Employer Provided Innovation Challenges (EPIC) program, bringing hands-on, real-world learning into Georgia classrooms and spotlighting the state’s growing leadership in workforce innovation.

 

Through this groundbreaking initiative, GLS developed and piloted three challenge-based projects designed to spark student interest in the life sciences:

  • Navigating Medical Device Regulatory Pathways
  • Innovative Solutions in Food Production
  • Automated Biomanufacturing

 

Over 60 high school students across the state formed 12 teams to tackle these challenges, working directly with industry volunteer mentors to co-design creative solutions. All participants earned credentials for their work, demonstrating not only career awareness but real-world readiness for Georgia’s growing bioscience sector.

 

One standout team—composed of homeschool students from the Georgia Black Home Educators Network (GBHEN), sponsored by Blue Heron Urban Farm and Sanctuary—was selected to present at the EPIC National Convening on June 24 in Washington, D.C., hosted at the U.S. Chamber of Commerce. The team shared their innovations in sustainable food production, highlighting the role of student ingenuity in solving global challenges.

 

“This program gave students a window into the real world of biotech, medical devices, and agtech,” said Dr. Phil Gibson, Executive Director for the Georgia Life Sciences Institute. “It also gave our industry partners a powerful new way to engage with the future workforce—and even shape it.”

 

EPIC, launched by the U.S. Chamber Foundation, is redefining the connection between business innovation and workforce development by giving students access to real problems, real collaboration, and real career exposure.

 

This effort is part of Georgia Life Sciences’ broader mission to build a sustainable talent pipeline in the life sciences—from classroom to career. Through initiatives like this partnership with the Us Chamber Foundation and the public/private partnership with Georgia’s Department of Education, the Biotech Teacher Training Initiative (BTTI), GLS provides immersive, standards-aligned professional development for Georgia educators to bring modern biotech concepts and techniques into biology, chemistry, agriculture, and environmental science classrooms statewide.

 

Why It Matters

As Georgia’s life sciences industry continues to grow, workforce demand is outpacing supply. Programs like EPIC play a vital role in bridging that gap by increasing industry awareness early in the pipeline. Building student familiarity with bioscience careers—and connecting them with real industry mentors—is essential to strengthening Georgia’s long-term competitiveness in biotechnology, biomanufacturing, and global health innovation.

 

About Georgia Life Sciences

Georgia Life Sciences is the statewide association advancing the life sciences ecosystem through policy advocacy, economic development, workforce initiatives, and industry-led innovation. From breakthrough biomanufacturing to patient access, GLS is committed to making Georgia a leader in global health and biotechnology.

Biotech Leaders Launch National Alliance to Define the Future of American Innovation

May 5, 2026
New coalition forms to develop a national innovation roadmap to strengthen and extend  America’s global leadership in biotechnology

UGA & Manus Among Awardees in $214M BioMADE Investment

April 30, 2026
BioMADE Announces $21.4 Million Invested in 14 Projects to Develop the U.S. Bioindustrial Manufacturing Industry and Advance National Security Priorities

Nutrivert announces first close on $6 million Series A-2 funding round

April 17, 2026
April 17, 2026 - Nutrivert Inc., a developer of non-antibiotic replacements for antibiotic growth promoters in livestock, today announced it has completed the first close, raising $2.375 million, of its Series A-2 funding round of $6 million. The round was led by global animal health investor Arrow Ventures with participation from other investors. The funding will be used to further develop Nutrivert’s manufacturing, human food safety and target animal safety and efficacy packages for the company’s lead product Nutrivert LDPP. Nutrivert LDPP is a proprietary, novel, orally available, lipidated synthetic enantiomeric desmuramyl analog of muramyl dipeptide, the smallest conserved immunoactive component of bacterial peptidoglycan. LDPP has no antibacterial effect but has consistently promoted growth and improved feed efficiency in pig studies. LDPP binds to the mammalian NOD2 receptor and is the only NOD2 ligand reported to inhibit the inflammatory signal NF-κB. In pilot studies, LDPP rescued 70kg pigs from an otherwise lethal dose of porcine reproductive and respiratory syndrome virus (PRRSV) and abrogated influenza disease symptoms in piglets. The Company intends to develop LDPP for all major livestock species worldwide. Patents have been granted in most major markets. The global antibiotic growth promoter market is worth an estimated $5.8 billion. Approximately 73% of all antibiotics are fed to livestock. The market is believed to be the world’s largest drug market by volume, with ~100,000 tons of active pharmaceutical ingredient administered annually. FDA’s latest data, for 2024, show a 13% rise in U.S. livestock antibiotic use since 2017. The Food and Agriculture Organization reports that livestock antibiotics are mostly given to speed animal growth. Regulators and non-governmental organizations have called for reduction of antibiotic use in livestock, citing concerns that the global, intensive use of antibiotics, often at subtherapeutic doses, selects for antimicrobial resistance: bacteria that are “immune” to antibiotics and that therefore pose a threat to public health. Spillovers of antibiotic-resistant bacteria from livestock to humans have been documented. “Nutrivert LDPP has consistently improved feed efficiency in pigs without antibiotics,” said Bernhard Kaltenboeck, CSO. “We are excited to have the support of Arrow Ventures and our other investors in bringing a new tool that will help producers reduce production costs and reduce selection pressure for antimicrobial resistance.” About Nutrivert LDPP: LDPP is an investigational compound currently undergoing clinical evaluation. It has not been approved by the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), or any other global regulatory authority for any indication. The safety and efficacy of LDPP have not been established. Any mention of potential use is based on preliminary data and does not guarantee future regulatory clearance or commercial availability.
MORE POSTS